Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders

摘要

A formulation containing: a) 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone at concentrations of 6 mg/ml; b) one or more polyoxyhydrocarbyl compounds and c) one or more pharmaceutically acceptable surfactants wherein one of the surfactants is PEG-400 at a concentration of 0.01-10g/ml and at least one of the polyoxyhydrocarbyl compounds is ethoxylated castor oil at a concentration of 0.01-10 g/ml. A formulation containing: a) 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone at concentrations of 4.5 mg/ml; b) 0.45g/ml pf PEG-400; c) 0.315 g/ml of CREMAPHOR EL; d) 20 mg benzyl alcohol; and e) 0.095g/ml of ethanol. These formulations can be used to treat abnormal conditions such as cell proliferative disorders.